Why United Therapeutics' Adcirca Could Witness Strong Revenue Growth - Market Realist
Market RealistWhy United Therapeutics' Adcirca Could Witness Strong Revenue GrowthMarket RealistDespite not changing its price levels for the past five years, in April 2016, United Therapeutics' (UTHR) Remodulin managed to surpass its past monthly sales figures.
Sell-side Focus: United Therapeutics Corporation (NASDAQ:UTHR) - Markets Daily
Sell-side Focus: United Therapeutics Corporation (NASDAQ:UTHR)Markets DailyIts therapeutic products and product candidates include: Prostacyclin Analogues, Phosphodiesterase Type 5 (PDE-5) Inhibitor, Adcirca, Monoclonal Antibodies (MAbs), Glycobiology Antiviral Agents, Cell-Based Therapy, and Engineered Lungs and Lung .
Adcirca (Tadalafil) - Pulmonary Hypertension News
Adcirca (Tadalafil)Pulmonary Hypertension NewsMarketed under the name Adcirca by Eli Lilly (who later sold its exclusive commercialization rights for the drug in the U.
Introducing United Therapeutics: Your Insider Overview - Market Realist
Market RealistIntroducing United Therapeutics: Your Insider OverviewMarket RealistThe above diagram shows the key drugs marketed by United Therapeutics (UTHR), which involve Adcirca, Tyvaso, Remodulin, Unituxin, and Orenitram.
Gileads Letairis Gets FDA Nod in Combination with Adcirca - Zacks.com
CNA FinanceGileads Letairis Gets FDA Nod in Combination with AdcircaZacks.